Catherine Sabatos-Peyton, Larkspur CEO
May 23, 2023 10:51 AM EDT
Financing
Startups

Lark­spur Bio­sciences kicks off with $30M+, hunt­ing for new on­col­o­gy im­munother­a­pies

Paul Schloesser

Associate Editor

Based in Mass­a­chu­setts, Lark­spur Bio­sciences, a biotech fo­cused on de­vel­op­ing new im­muno-on­col­o­gy treat­ments, is now armed with $35.5 mil­lion in com­bined …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Trump blog: Judge ex­tends na­tion­wide block on NIH pay­ment cuts

RFK Jr. read­ies re­view of child­hood vac­cine sched­ule af­ter pledg­ing not to

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times